Eisai, Merck Sue Dr. Reddy’s to Block Generic Copies of Lenvima

Eisai Co. Ltd. and Merck & Co. accused a generic version of Lenvima proposed by Dr. Reddy’s Laboratories Ltd. of infringing three patents for the blockbuster cancer drug.

Two of the patents—US Patent Nos. 11,186,547 and 10,407,393—cover a high-purity quinoline derivative and a method for making it, according to a complaint filed Thursday in the US District Court for the District of New Jersey. They’re also part of Eisai and Merck’s 2019 case against Shilpa Medicare Ltd., pending in the same district court. Both patents expire in August 2035, according to Lenvima’s entry in the US Food and Drug ...